Gene therapy against hemophilia

Hannover Medical School (MHH) is one of the first institutions in Germany to be authorized to carry out a new innovative treatment for haemophilia A and B

07-Oct-2024 - Cell and gene therapies are on the rise. This is a new glimmer of hope for people with previously untreatable or barely treatable diseases. Another new therapeutic method has now been added to the list: gene therapy for hemophilia, also known as bleeding disorder. The Hemophilia Center at ...

Sanofi to acquire Bioverativ for $11.6 billion

23-Jan-2018 - Sanofi and Bioverativ Inc. have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion (on a fully diluted basis). The transaction wasunanimously ...

Bioverativ to acquire biotechnology company True North Therapeutics

26-May-2017 - Bioverativ Inc., a biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, announced that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a ...

Baxalta gains Health Canada approval for OBIZUR

Treatment for patients with acquired hemophilia A

19-Oct-2015 - Baxalta Incorporated announced that Health Canada has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in patients with acquired hemophilia A caused by autoantibodies to coagulation Factor VIII (FVIII), a very rare and life-threatening ...

FDA Grants Orphan Status for ATX-F8-117 for the treatment of Haemophilia A patients in the US

11-Jun-2015 - Apitope announced that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration (FDA) for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors. Commenting on the ...

Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market

Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan

11-May-2015 - Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to ...

Sobi receives orphan drug designation for Elocta in Switzerland

17-Apr-2015 - Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides ...

Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study

04-Mar-2015 - Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia ...

Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A

27-Nov-2014 - Apitope announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A.Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the ...

PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients

Current evidence does not confirm increased risk of inhibitor development compared with other factor VIII products

10-Dec-2013 - The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the medicines Kogenate Bayer and Helixate NexGen and concluded that current evidence did not confirm an increased risk of developing antibodies (factor VIII inhibitors) against these medicines when ...